Lakewood-Amedex Biotherapeutics Inc. (LABT) — Institutional Holders, Q2 2026
6 institutional investment managers reported a LABT position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $166.7K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
LABT 13F holders ranked 1–6 of 6
| # | Institution | Shares | Value | % of portfolio | QoQShares vs prior Q |
|---|---|---|---|---|---|
| 1 | Marex Group plc#1 · 48,167 sh | 48,167 | $151.2K | <0.01% | — |
| 2 | UBS Group AG#2 · 4,098 sh | 4,098 | $12.9K | 0.00% | — |
| 3 | Tower Research Capital (TRC)#3 · 624 sh | 624 | $2.0K | 0.00% | — |
| 4 | OSAIC#4 · 138 sh | 138 | $433.00 | 0.00% | — |
| 5 | HRT FINANCIAL#5 · 44,782 sh | 44,782 | $140.00 | 0.00% | — |
| 6 | Ronald Blue#6 · 11 sh | 11 | $35.00 | — | — |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for the prior quarter without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.